AZD-9291 | Osimertinib | Mereletinib CAS 1421373-65-0 AZD9291 Lungenkrebsbehandlung Active Pharma Ingredient Vertriebskontakte. Verwendung von Chemikalien zur Krebsmedikamentenforschung nur zum Verkauf. AZD-9291 Reinheit 99% available
AZD-9291 | Osimertinib | Mereletinib CAS 1421373-65-0
AZD-9291
Andere Namen: N(2{[2(diMethylaMino)Ethyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}Phenyl)prop2enaMide;N-[2-[[2-(Dimethylamino)Ethyl]Methylamino]-4-Methoxy-5-[[4-(1-Methyl-1H-indol-3-yl)-2-Pyrimidinyl]Amino]Phenyl]-2-Propenamid;AZD9291,AZD-9291
CAS: 1421373-65-0
MF: C28H33N7O2
MW: 499.61 .
AZD 9291 ist ein irreversibler Inhibitor des epidermalen Wachstumsfaktorrezeptors (EGFR) sensibilisierende und T790M-Resistenzmutationen (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 und 16.2 μM, jeweils). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.
